||||||||||||I|| US005266490A United States Patent (19) 11 Patent Number: 5,266,490 Davis et al. 45 Date of Patent: Nov.30, 1993 (54) MAMMALIAN EXPRESSION VECTOR Maniatis et al. (1990), Molecular Cloning: A Laboratory Manual, vol. 2, pp. 16.3-16.81. 75 Inventors: Samuel Davis, New York; George D. Martson (1987), DNA Cloning: A Practical Approach, Yancopoulos, Briarcliff Manor, both vol. 3, Chap. 4, pp. 59-88. of N.Y. Mizushima et al. (1990), Nucl. Acids Res. 18 (17): 5322. 73) Assignee: Regeneron Pharmaceuticals, Inc., Sambrook et al. (1988), Focus 10(3): 41-48. Tarrytown, N.Y. Simmons et al. (1988), J. Immunol. 141 (8): 2797-2800. Spector (1985), Genet. Engineering 7: 199-234. (21) Appl. No.: 678,408 Stamenkovic et al. (1988), J. Exp. Med. 167: 1975-1980. (22 Filed: Mar. 28, 1991 Urlaub et al. (1980), Proc. Nat. Acad. Sci USA 77(7): 51) Int. Cl.5...................... C12N 15/79; C12N 15/12; 426-4220. C12N 15/18 Woeltje et al. (1990), J. Biol. Chem. 265 (18): 10720-10725. 52) U.S. C. ................................ 435/320.1; 536/23.4; Wysocki et al. (1978); Proc. Nat. Acad. Sci USA 75(6): 536/23.5; 536/24.1 2844-2848. 58) Field of Search ................. 435/320.1, 69.1, 172.3; Seed, B. (Oct. 1987), Nature, vol. 329, pp. 840-842. 536/27, 24.1, 23.4, 23.5 Yanisch-Perron et al. (1985), Gene, vol. 33, pp. (56) References Cited 103-119. PUBLICATIONS Seed et al. (May, 1987), Proc. Nat. Acad. Sci USA, vol. 84, pp. 3365-3369. Alt et al. (1978), J. Biol. Chem. 253(5):1357-1370. Andersson et al. (1989), J. Biol. Chem. 264(14): Primary Examiner-Richard A. Schwartz 8222-8229. Assistant Examiner-Philip W. Carter Aruffo et al. (1989), J. Immunol. 143(5): 1723-1730. Attorney, Agent, or Firm-Pennie & Edmonds Aruffo et al. (1987), Proc. Nat. Acad. Sci USA 84: 57 ABSTRACT 8573-8577. Bebbington et al. (1987), DNA Cloning: A Practical DNA plasmid expression vector, pCMX, enables Approach, vol. 3, Chapter 8, pp. 163-168, 188. cDNA expression cloning in mammalian cell culture. Boulay et al. (1990), Biochem. Biophys. Res. Comm. This novel expression vector exhibits a marked increase 168(3): 1103-1109. in gene expression when compared to its parental plas Cunningham et al. (1991), Science 254; 821-825. mid construction. Kenny et al. (1989), SV40 DNA Replication. In Vitro, NATO ASl Series, vol. 434, pp. 437-448. 7 Claims, 7 Drawing Sheets U.S. Patent Nov. 30, 1993 Sheet 1 of 7 5,266,490 ACGCTTGAC ATTGATTATTGACTATTAT TAATAGTAAT CAATTACGGG GTCATTATT 60 CATAGCCCAT ATATGATT CCGCTTACA TAACTTACGG AAATGGCCC CGCCTGGCTG 120 ACCGCCCAAC GACCCCCGCC CATTGACGTC AATAATGACG TATGTTCCCA TAGTAACGCC 18O AATAACTTTCCATTGAC GTCAATGGGT GACTATTTA CGGTAAACTG CCCACTTGGC 240 ATACATCAA GTGTATCATA TGCCAAGTAC GCCCCCTATTGACGTCAATG ACTAAATG 300 GCCCCCT CATTATGCCC ATACATAC CTTATGGGAC TTTCCTACTT GGCATACAT 360 CTACGTATTA GTCATCGCTA TTACCATGGT GATGCGGTTTTGGCAGTACA TCAATGGGCG 420 TGGATAGCGGTTTGACTCACGGGGATTTCC AAGTCTCCAC CCCATTGACGTCAATGGGAG 480 TTTTTTT CACCAAAATC AACGGGACTT TCCAAAATGT CGTAACAACT CCGCCCCATT 540 GACCAAATGGGCGTAGGC GTGTACGTGGGAGTCTATATAAGCAGA CTCTCTGGCT 600 AACTAGAGAA CCCACTGCTT ACTGGCTTAT CGAAATTAAT ACACTCACT ATAGGGAGAC 660 CGGAAGCTTC TAGAGATCCC TCACCCA GATCCATTT GCTGGCGCGG ATTCTTTATC 720 ACTGATAAGT TGGTGGACAT ATTATGTTTA TCAGTGATAA AGTGTCAAGC ATGACAAAGT 780 TCAGCCGAA TACATGATC CTGCCGCCC TAGACCTGTTGAACGAGGTC GGCGTAGACG 840 TCTGACAC ACCAAACTG GCGGAACGGT TGGGGTTCA GCAGCCGC CTTTACTGGC 900 ACTTCAGGAA CAAGCGGGCGCTCTCGACCACTGGCCGA AGCCATGCTGGCGGAGAATC 960 ATACACTTC GTGCCGAGA GCCACAC ACTGGCGCTC ATTTCTACT GGGAATGCCC 020 GCAGCTTCAGGCAGGCGCTG CTCGCCTACC GCCAGCACAA TGGATCTCGA GGGATCTTCC 080 F.G. 1A U.S. Patent Nov. 30, 1993 Sheet 2 of 7 5,266,490 ATACCTACCA GTTCTCCC TGCAGTCGC GGCCGCGACT CAGAGATC TTTTGAAGG 1140 AACCTTACTT CTTGTGT ACATAATTGACAAACTACC TACAAGATT TAAAGCTCTA 1200 AGTAAATAT AAAATTTTTA ATTATAAT GTGITAAACT ACTGATTCTA ATTGTTTGTG 1260 TATTTTAGAT TCCAACCTAT GGAACTGATG AATGGGAGCA GTGGTGGAAT GCCTTTAATG 320 AGGAAAACCT GTTTTGCTCA GAAGAAATGC CATCTATA TGATAGCT ACTGCTGACT 1380 CTCAACATTC TACTCCTCCAAAAAAGAAA GAAAGTAGA AGACCCCAAG GACTTTCCTT 440 CAAATTGCT AAGTTTTTTG ATCATGCTG TGTTTAGAA TAGAACTCTT GCTTGCTTTG 1500 CTATTTACAC CACAAAGGAA AAAGCTGCAC TGCTATACAA GAAAATTATG GAAAAATATT 560 CTTAACCTT TATAAGTAG CATAACAGTT AAATCATAA CATACTGTTTTTTCTTACTC 1620 CACACAGGCA TAGAGTTCT GCTATTAATAACTATGCTCA AAAATTTGT ACCTTTAGCT 680 TTTTAATTT TAAAGGGTT AATAAGAAT ATTTGATTA TATGCCTT ACTAGAGATC 1740 ATAATCAGCC ATACCACATT TTAGAGGTT TACTGT TAAAAAACCT CCCACACCTC 1800 CCCCTGAACC TAAACATAA AATAATGCA ATTTTTTG TTAACTTTT TATTGCACT 1860 TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA CAAATAAAGC ATTTTTTTCA 1920 CTGCATTCTA GTGTGGTTT GTCCAAACTC ATCAATGTAT CTTATCATGT CTGATCCTT 1980 ACTCCCCCA TCCCCCCCT AACTCCCCC ATTCCGCCC ATTCTCCGCC CCATGCTA 2040 F.G. 1B U.S. Patent Nov. 30, 1993 Sheet 3 of 7 5,266,490 CTAATTTTTTTTATTTATGC AAGGCCGAGGCCGCCTCGCCTCTGAGCT ATTCCAGAAG 2100 TAGTAGGAGGCTTTTTTGG AGGCCTAGGC TTTTGCAAAA AGGAGCTCCC AGCAAAAGGC 260 CAGGAACCGT AAAAAGGCCGCGTTGCTGGC GTTTTTCCAT AGGCTCCGCC CCCCTGACGA 2220 GCATCACAAA AATCGACGCT CAATCAGAG. GTGGCGAAAC CCGACAGGAC TATAAAGATA 2280 CCAGGCTTT CCCCCTGGAA GCTCCCTCT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC 2340 CGATACCTG TCCCCTTTC TCCCTTCGGG AACTGGCG CTTTCTCAAT GCTCACGCTG 2400 TAGTATCTC ATTCGGTT AGGTCGTTCG CTCCAAGCTG GGCTTGTGC ACAACCCCC 2460 CTTCAGCCC GACCCTGCGCCTTATCCGG TAACTATCGT CTTGATCCA ACCCGGTAAG 2520 ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTACAAG CGAGGTATT 2580 AGGCGTGCT ACAGATTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAT 2640 ATTTGGTATC TGCGCTCTC TGAAGCCAT TACCTTCGGA AAAAAGTTG GTAGCTCTT 2700 ATCCGGCAAA CAAACCACCGCTGGTAGCGG, TGGTTTTTTT GTTTGCAAGC AGCAGATTAC 2760 GCCAGAAAA AAAGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGT CTGACGCTCA 2820 GTGGAACAA AACTCACGTT AAGGGATTTT GTCATGAGA TTATCAAAAA GGATCTTCAC 2880 CTAGATCCTT TTAAATAAA AATGAATTT TAAATCAATC TAAAGTATAT ATAGTAAAC 2940 TTGTCTGAC ATACCAAT GCTTAATCAG TAGGCACCT ATCTCACGA TCTTCTATT 3000 FIG. 1C U.S. Patent Nov. 30, 1993 Sheet 4 of 7 5,266,490 TCTTCATCC ATAGTTCCT. GACTCCCCGT CTGTAGATA ACTACGATAC GGGAGGGCTT 3060 ACCATCTGGC CCCATCTG CAATGATACC GCGAGACCCA CGCTCACCG CTCCAGATTT 320 ATCAGCAATA AACCAGCCAGCCGGAAGGGC CGAGCCAGA AGTGGTCCTG CAACTTTATC 3180 CGCCTCCATC CATCTATTA ATTTTGCCG GMCA: GTAAGTATT CGCCATTAA 3240 TAGTTTCGC AACTTTTG CCATTGCTAC AGGCATCTGGTTCACGCT CGTCGTTTG 3300 TATGGCTTCATTCACTCCGGTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT 3360 GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC 3420 AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCATGCCATCCGT 3480 AAGATGCTTT TCTTGACTG TAGTACTC AACCAAGTCA TCTGAGAAT AGTGTATGCG 3540 GCGACCGAGT TGCTCTTGCC CGGCTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC 3600 TTTAAAAGTG CTCATCATTG GAAAACTTC TTCGGGCGA AAACTCTCAA GATCTTACC 3660 GCTTTGAGA TCCATTCGA TGTAACCCAC TCTGCACCC AACTGATCTT CAGCATCTTT 3720 TACTTTCACC AGCGTTTCTGGGTGAGCAAA AACAGGAAG CAAAATGCCG CAAAAAAGGG 3780 AATAAGGGC ACACGGAAA GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG 3840 CATTTATCA GTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA 3900 ACAAATAGGGGTTCCGCCA CATTTCCCC AAAAGTGCCA CCTG 3944 FIG.1D U.S. Patent Nov. 30, 1993 Sheet 5 of 7 5,266,490 A MUAVP CENE CST SW400R B: Sri pro - DBMHSORT ( pcEM42 PBR OR 1. PCR WITH BAM B C & D PRIVERS, 1. DIGEST WITH 1. PCR WITH SST1 A B PRER. 2. DIGEST PCR MLU, BAM, AND PRODUCT WITH SOLATE FRAGMENT. 2. DIGEST PCR BAW, SST1 PRODUCT WITH '''SV40 MLU, SST, MLU MLU SST BAM CNN (MP POLY LIGATE NKER PBR OR SSTN MLU / BAM 7AMP CN pCMX PBR OR POLYNKER FIG.2 U.S. Patent Nov. 30, 1993 Sheet 6 of 7 5,266,490 | / | U.S. Patent Nov. 30, 1993 Sheet 7 of 7 5,266,490 sO S. N. S. S. S. itC Z isO Z 59 is 9 5,266,490 1. 2 sible for intron splicing and polyadenylation of mRNA MAMMALIAN EXPRESSION VECTOR transcripts. This contiguous region of the promoter polylinker-polyadenylation site is commonly referred to 1. INTRODUCTION as the transcription unit. The vector will also contain (4) The present invention relates to the construction and a selectable marker gene(s) (e.g., the B-lactamase gene), utilization of a DNA plasmid vector, in particular, often conferring resistance to an antibiotic (such as pCMX. This vector promotes the expression of cloned ampicillin), allowing selection of initial positive trans genes when transfected into mammalian cell lines. The formants in E. Coli; and (5) sequences facilitating the functional portions of pCMX include the immediate replication of the vector in both bacterial and mamma early promoter of human cytomegalovirus (HCMV), a 10 lian hosts. "polylinker' sequence facilitating the insertional clon An example of such an expression vector is CDM8 ing of DNA sequences, an RNA splice and polyadeny (Seed, 1987, Nature 329: 840-842; Seed and Aruffo, lation signal, origins of replication from SV40 (for repli 1987, Proc. Natl. Acad. Sci. USA 84:3365-3369; Aruffo cation in COS cells) and pBR322 (for replication in E. and Seed, Proc. Natl. Acad. Sci., USA 84: 8573-8577), coli), and the gene encoding 3-lactamase, a selectable 15 the parental plasmid to the pCMX plasmid of the pres marker conferring resistance to ampicillin in bacterial ent invention. The transcription unit of CDM8 is com cells. The invention can be used to transiently or stably posed of a chimeric promoter (the human cytomegalo express eukaryotic genes within mammalian cells, that virus AD169 constitutive promoter fused to the T7 can provide an environment conducive to appropriate RNA polymerase promoter), a polylinker region and protein folding or other eukaryotic protein modifica 20 the SV40 small tumor (t) antigen splice and early region tions such as glycosylation and oligomerization. polyadenylation signals derived from